Amicus Therapeutics Stock Forecast, Price & News

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Amicus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FOLD, but not buy additional shares or sell existing shares.
View analyst ratings for Amicus Therapeutics or view top-rated stocks.

Wall Street analysts have given Amicus Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amicus Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Amicus Therapeutics.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings results on Sunday, May, 9th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.01. The biopharmaceutical company had revenue of $66.40 million for the quarter, compared to analysts' expectations of $71.76 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 80.85% and a negative net margin of 95.05%.
View Amicus Therapeutics' earnings history.

Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FOLD stock has increased by 23.1% and is now trading at $9.91.
View which stocks have been most impacted by COVID-19.

Amicus Therapeutics updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $300 million-315 million, compared to the consensus revenue estimate of $312.64 million.

13 analysts have issued 1-year price objectives for Amicus Therapeutics' shares. Their forecasts range from $13.00 to $31.00. On average, they expect Amicus Therapeutics' share price to reach $20.42 in the next twelve months. This suggests a possible upside of 106.0% from the stock's current price.
View analysts' price targets for Amicus Therapeutics or view top-rated stocks among Wall Street analysts.

21 employees have rated Amicus Therapeutics CEO John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among Amicus Therapeutics' employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Amicus Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of FOLD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Amicus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (8.59%), BlackRock Inc. (8.09%), Redmile Group LLC (7.94%), Morgan Stanley (3.75%), Palo Alto Investors LP (3.67%) and Janus Henderson Group PLC (3.38%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends for Amicus Therapeutics.

FOLD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Morgan Stanley, D. E. Shaw & Co. Inc., Janus Henderson Group PLC, Perceptive Advisors LLC, Bank of New York Mellon Corp, Nuveen Asset Management LLC, and BlackRock Inc.. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Margaret G Mcglynn, and Samantha Prout.
View insider buying and selling activity for Amicus Therapeutics or view top insider-selling stocks.

FOLD stock was bought by a variety of institutional investors in the last quarter, including Fiera Capital Corp, Deerfield Management Company L.P. Series C, Palo Alto Investors LP, Healthcare of Ontario Pension Plan Trust Fund, Voloridge Investment Management LLC, Jennison Associates LLC, Grosvenor Holdings L.L.C., and New York State Common Retirement Fund. Company insiders that have bought Amicus Therapeutics stock in the last two years include Burke W Whitman, and Lynn Dorsey Bleil.
View insider buying and selling activity for Amicus Therapeutics or or view top insider-buying stocks.

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FOLD stock can currently be purchased for approximately $9.91.

Amicus Therapeutics has a market capitalization of $2.64 billion and generates $260.89 million in revenue each year. The biopharmaceutical company earns $-276,850,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

Amicus Therapeutics employs 483 workers across the globe.

The official website for Amicus Therapeutics is www.amicusrx.com.

Amicus Therapeutics is headquartered at 1 Cedar Brook Drive, Cranbury NJ, 08512.

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]